Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

422 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term durability of dolutegravir plus darunavir/cobicistat dual regimen in highly antiretroviral-experienced people with HIV (DoDaco study).
Ripamonti D, Comi L, Francavilla A, Valenti D, Cossu MV, Moschese D, Lapadula G, Mezzadri L, Bonfanti P, Mazzitelli M, Cattelan A, Gulminetti R, Pagnucco L, Fabbiani M, Bini T, Zazzi M, Giacomelli A. Ripamonti D, et al. Among authors: lapadula g. J Antimicrob Chemother. 2025 Jun 3;80(6):1665-1672. doi: 10.1093/jac/dkaf119. J Antimicrob Chemother. 2025. PMID: 40202851
CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
Torti C, Lapadula G, Barreiro P, Soriano V, Mandalia S, De Silvestri A, Suter F, Maggiolo F, Antinori A, Antonucci F, Maserati R, El Hamad I, Pierotti P, Sighinolfi L, Migliorino G, Ladisa N, Carosi G; Italian MASTER Cohort. Torti C, et al. Among authors: lapadula g. J Antimicrob Chemother. 2007 Jun;59(6):1141-7. doi: 10.1093/jac/dkm100. Epub 2007 Apr 13. J Antimicrob Chemother. 2007. PMID: 17434879
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy.
Meini G, Rossetti B, Bianco C, Ceccherini-Silberstein F, Di Giambenedetto S, Sighinolfi L, Monno L, Castagna A, Rozera G, D'Arminio Monforte A, Zazzi M, De Luca A; ICONA Foundation Group. Meini G, et al. J Antimicrob Chemother. 2014 Mar;69(3):735-41. doi: 10.1093/jac/dkt426. Epub 2013 Oct 23. J Antimicrob Chemother. 2014. PMID: 24155059 Free PMC article.
Survival in HIV-infected patients after a cancer diagnosis in the cART Era: results of an italian multicenter study.
Gotti D, Raffetti E, Albini L, Sighinolfi L, Maggiolo F, Di Filippo E, Ladisa N, Angarano G, Lapadula G, Pan A, Esposti AD, Fabbiani M, Focà E, Scalzini A, Donato F, Quiros-Roldan E; Master Cohort Group. Gotti D, et al. Among authors: lapadula g. PLoS One. 2014 Apr 23;9(4):e94768. doi: 10.1371/journal.pone.0094768. eCollection 2014. PLoS One. 2014. PMID: 24760049 Free PMC article.
Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort study.
Raffetti E, Albini L, Gotti D, Segala D, Maggiolo F, di Filippo E, Saracino A, Ladisa N, Lapadula G, Fornabaio C, Castelnuovo F, Casari S, Fabbiani M, Pierotti P, Donato F, Quiros-Roldan E; MASTER Cohort. Raffetti E, et al. Among authors: lapadula g. BMC Public Health. 2015 Mar 12;15:235. doi: 10.1186/s12889-015-1565-0. BMC Public Health. 2015. PMID: 25884678 Free PMC article.
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study.
Mussini C, Lorenzini P, Cozzi-Lepri A, Lapadula G, Marchetti G, Nicastri E, Cingolani A, Lichtner M, Antinori A, Gori A, d'Arminio Monforte A; Icona Foundation Study Group. Mussini C, et al. Among authors: lapadula g. Lancet HIV. 2015 Mar;2(3):e98-106. doi: 10.1016/S2352-3018(15)00006-5. Epub 2015 Feb 6. Lancet HIV. 2015. PMID: 26424550
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir.
Gagliardini R, Bandera A, Zaccarelli M, Sterrantino G, Latini A, D'Avino A, Lapadula G, Antinori A, Cauda R, De Luca A, Gori A, Di Giambenedetto S, Fabbiani M. Gagliardini R, et al. Among authors: lapadula g. Antivir Ther. 2018;23(2):139-148. doi: 10.3851/IMP3188. Antivir Ther. 2018. PMID: 28799920
422 results